A study published in JAMA Internal Medicine examined whether achieving serum urate levels below 6 mg/dL with urate-lowering therapy (ULT) is associated with reduced cardiovascular risk in patients with gout (n = 109,504; mean age, 62.9 years). Patients in the treat-to-target (T2T) ULT group demonstrated higher 5-year cardiovascular event-free survival (difference, 1.0%) and a lower risk of major adverse cardiovascular events (MACE; HR, 0.91) compared with those in the non-T2T ULT group. These associations were more evident among patients with high or very high cardiovascular risk than among those with moderate risk.
Notably, patients achieving serum urate levels below 5 mg/dL showed greater benefits, including higher 5-year event-free survival (difference, 2.6%) and a larger reduction in MACE risk (HR, 0.77). These findings suggest that achieving serum urate levels below 6 mg/dL with…
